Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors—United States, July 2016–June 2019

Details

• Alternative Title:
  Clin Infect Dis
• Personal Author:
  Gold, Jeremy A. W. ; Tolu, Seda S. ; Chiller, Tom ; Benedict, Kaitlin ; Jackson, Brendan R.
• Description:
  We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).
• Subjects:
  Adenine Article Cancer Humans Ibrutinib Incidence Invasive Fungal Infections Opportunistic Infections Piperidines Small Molecule Kinase Inhibitors United States

  More +
• Source:
  Clin Infect Dis. 75(2):334-337
• Pubmed ID:
  34893821
• Pubmed Central ID:
  PMC9184298
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  75
• Issue:
  2
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:127b290a3fdb2dd98e805e104be82a7f553a554af55f52e9fc6d8e31ecdc3bcb
• Download URL:
  https://stacks.cdc.gov/view/cdc/119253/cdc_119253_DS1.pdf
• File Type:
  [PDF - 304.29 KB ]